A mother's persistence helps revive an all-but-abandoned drug class and could aid her son and thousands of others with ...

Parents of children with the rare genetic disease Duchenne muscular dystrophy (DMD) are appealing to the government, the ...

Posters will be showcased at various times throughout the day in the Exhibit Hall. The full MDA 2026 Conference program is available at mdaconference.org. The Edgewise presentation and posters will be ...

Nearly three-quarters of adults who identify as MAGA supporters now also identify as MAHA backers. Half of respondents who ...

Wedbush initiated coverage on Solid Biosciences, Inc. (NASDAQ:SLDB), a gene therapy company focused on treating Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive ...

Muscular dystrophy, known as DMD, is a rare and fatal genetic disease that primarily affects boys, slowly robbing them of their ability to walk, breathe and live independently. Until now, there have ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...

Sarepta Therapeutics has come under pressure following the deaths of three patients using its treatments.

Minnesota (WCCO) -- An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment. Colton Belluzzo was diagnosed with a form of muscular ...

– Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is sponsoring ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...